<div class="headers"><div>Table 1. Demographic and clinical characteristics at baseline</div><div>Fig. 1 Annualized rate of moderate/severe and all (mild/moderate/severe) exacerbations. n, number of patients included in the analysis; N, total number of patients in the study. b.i.d., twice daily; CI, confidence interval; IND/GLY, indacaterol/glycopyrronium 110/50 µg o.d.; o.d., once daily; SFC, salmeterol/fluticasone 50/500 µg b.i.d</div><div>Figure 2 and Figure 3 The analyses were performed in the full analysis set from the FLAME study. Subjects who did not experience a COPD exacerbation were censored at the earlier date of last double-blind treatment + 1, death and final visit. Figure truncated after Week 52 (Day 365). b.i.d., twice daily; CI, confidence interval; HR, hazard ratio; IND/GLY, indacaterol/glycopyrronium 110/50 µg o.d.; o.d., once daily; SFC, salmeterol/fluticasone 50/500 µg b.i.dDemographic and clinical characteristics at baseline for the randomized set has been presented. Data are presented as mean<U+2009>±<U+2009>SD unless otherwise stated. P-values are based on t-tests for continuous variables and chi-square tests (or Fisher’s exact test as appropriate) for categorical variables. aon a scale of 0–40, with higher scores indicating worse health status; bon a scale of 0–4, with higher scores indicating more severe dyspnea
BMI body mass index, CAT COPD assessment test, COPD chronic obstructive pulmonary disease, FEV1 forced expiratory volume in 1<U+2009>s, FVC forced vital capacity, GOLD Global Initiative for Chronic Obstructive Lung Disease, ICS inhaled corticosteroid, LABA long-acting ß2-agonist, LAMA long-acting muscarinic antagonist, mMRC modified Medical Research Council, SD standard deviationMen</div><div>WomenMen n =<U+2009>2557</div><div>Women n =<U+2009>805</div><div>Pvalue</div><div>IND/GLY n/N</div><div>SFC n/N</div><div>IND/GLY vs SFC Rate ratio (95% Cl); P value</div><div>Time-to-first moderate/severe COPD exacerbations</div><div>HR (95% Cl): 0.79 (0.70-0.89); P< 0.001</div><div>HR (95% Cl): 0.76 (0.63-0.91); P= 0.004Age, years</div><div>65.2<U+2009>±<U+2009>7.7</div><div>62.6<U+2009>±<U+2009>7.6</div><div><<U+2009>0.001</div><div>Moderate/severe exacerbations</div><div>Men</div><div>1271/1295</div><div>1238/1255</div><div>0.81 (0.73-0.91): P< 0.001</div><div>Time-to-first all (mild/moderate/severe) COPD exacerbations.</div><div>HR (95% Cl): 0.86 (0.79-0.94); P= 0.001</div><div>HR (95% Cl): 0.80 (0.69-0.93); P = 0.005Duration of COPD, years</div><div>7.1<U+2009>±<U+2009>5.2</div><div>7.7<U+2009>±<U+2009>5.9</div><div>Women</div><div>380/380</div><div>418/424</div><div>0.89 (0.74-1.07); P= 0.225Current smoker, n (%)</div><div>946 (37.0)</div><div>387 (48.1)</div><div><<U+2009>0.001</div><div>All exacerbations</div><div>Men</div><div>1271/1295</div><div>1238/1255</div><div>0.88 (0,81-0,96);    0.003Estimated number of pack years</div><div>43.6<U+2009>±<U+2009>22.5</div><div>36.0<U+2009>±<U+2009>18.5</div><div><<U+2009>0.001</div><div>Women</div><div>380/380</div><div>418/424</div><div>0.88 (0.76-1.02); P = 0.078Severity of COPD (GOLD 2015), n (%) Low risk and more symptoms (Group B)</div><div>589 (23.0)</div><div>233 (28.9) High risk and more symptoms (Group D)</div><div>1945 (76.1)</div><div>569 (70.7)Severity of airflow limitation (GOLD 2011–2014), n (%) Moderate (GOLD 2)</div><div>804 (31.4)</div><div>319 (39.6)</div><div><<U+2009>0.001 Severe (GOLD 3)</div><div>1506 (58.9)</div><div>448 (55.7) Very severe (GOLD 4)</div><div>222 (8.7)</div><div>35 (4.3)Pre-bronchodilator FEV1, L</div><div>1.1<U+2009>±<U+2009>0.3</div><div>0.8<U+2009>±<U+2009>0.2</div><div><<U+2009>0.001Post-bronchodilator FEV1, L</div><div>1.3<U+2009>±<U+2009>0.3</div><div>1.0<U+2009>±<U+2009>0.3</div><div><<U+2009>0.001Post-bronchodilator FEV1, % predicted</div><div>43.5<U+2009>±<U+2009>9.5</div><div>45.8<U+2009>±<U+2009>9.0</div><div><<U+2009>0.001Post-bronchodilator FEV1 reversibility, % of baseline value</div><div>22.2<U+2009>±<U+2009>16.0</div><div>22.9<U+2009>±<U+2009>16.2Post-bronchodilator FEV1/FVC, %</div><div>40.9<U+2009>±<U+2009>9.9</div><div>43.7<U+2009>±<U+2009>9.5</div><div><<U+2009>0.001Number of COPD exacerbations in the previous year, n (%) 1</div><div>2094 (81.9)</div><div>616 (76.5) =<U+2009>2</div><div>461 (18.0)</div><div>188 (23.4)CAT scorea</div><div>16.5<U+2009>±<U+2009>7.0</div><div>17.7<U+2009>±<U+2009>7.1</div><div><<U+2009>0.001mMRCb, n (%) Grade 0–1</div><div>4 (0.2)</div><div>1 (0.1) Grade 2</div><div>1838 (71.9)</div><div>574 (71.3) Grade 3</div><div>660 (25.8)</div><div>211 (26.2) Grade 4</div><div>55 (2.2)</div><div>19 (2.4)BMI (kg/m2)</div><div>25.7<U+2009>±<U+2009>4.9</div><div>26.3<U+2009>±<U+2009>6.0ICS use, n (%)</div><div>1382 (54.0)</div><div>511 (63.5)</div><div><<U+2009>0.001LAMA use, n (%)</div><div>1535 (60.0)</div><div>502 (62.4)LABA use, n (%)</div><div>1651 (64.6)</div><div>606 (75.3)</div><div><<U+2009>0.001</div></div><table class='gmisc_table' style='border-collapse: collapse; margin-top: 1em; margin-bottom: 1em;' >
<thead>
<tr>
<th style='border-bottom: 1px solid grey; border-top: 2px solid grey;'> </th>
<th style='border-bottom: 1px solid grey; border-top: 2px solid grey; text-align: center;'>row/col</th>
<th style='border-bottom: 1px solid grey; border-top: 2px solid grey; text-align: center;'>1(A)</th>
</tr>
</thead>
<tbody>
<tr>
<td style='border-bottom: 2px solid grey; text-align: left;'>1</td>
<td style='border-bottom: 2px solid grey; text-align: left;'>35</td>
<td style='border-bottom: 2px solid grey; text-align: left;'></td>
</tr>
</tbody>
</table>
